Alcohol use disorder remains a significant public health challenge globally, ranking among the leading causes of morbidity and mortality. Despite its substantial social and medical ramifications, effective treatments are remarkably limited. Professor Jorge Manzanares, senior author of the study, emphasizes that elucidating the neurobiological transformations caused by long-term alcohol exposure is crucial for the rational design of next-generation therapies. The study’s focus on post-mortem human brain tissue confers a unique and highly translational perspective, addressing a critical gap in addiction neuroscience.

At the heart of this investigation lies the endocannabinoid system, a complex network comprising cannabinoid receptors (notably CB1 and CB2), endogenous ligands such as anandamide and 2-arachidonoylglycerol, and enzymatic regulators including FAAH and MGLL. The ECS orchestrates a wide array of central nervous system functions pivotal to mood, memory, stress response, and reward processing. Historically recognized for its role in modulating neural excitability, synaptic plasticity, and behavioral reinforcement, the ECS has been implicated increasingly in addiction pathways, though human data have remained scarce and fragmentary until now.

The research team concentrated on two fundamental nodes of the mesocorticolimbic system: the prefrontal cortex, known for governance over executive functions like planning and judgment, and the nucleus accumbens, a crucial hub for reward evaluation and the development of habitual behaviors. These regions were meticulously examined using mRNA quantification techniques to assess gene expression changes related to ECS components in individuals with chronic AUD versus control subjects without addiction history.

Results revealed a striking upregulation of the CB1 receptor gene, which surged by approximately 125% in the prefrontal cortex and 78% in the nucleus accumbens among individuals diagnosed with AUD. This finding aligns with CB1’s established role in reinforcing addictive behaviors and potentiating relapse susceptibility. Enhanced CB1 expression likely intensifies dopaminergic signaling within reward circuits, perpetuating compulsive alcohol seeking despite adverse consequences.

Conversely, the CB2 receptor gene exhibited a marked downregulation, decreasing by nearly half in both examined brain regions. Given CB2’s neuroprotective and anti-inflammatory functions, this reduction suggests a compromised endogenous defense mechanism against alcohol-induced neurotoxicity and neuroinflammation. The decline in CB2 signaling may further exacerbate neuronal damage and impair synaptic integrity in vulnerable circuits.

One of the most novel dimensions of the study was its exploration of GPR55, a receptor previously termed an ‘orphan’ due to ambiguous endogenous ligands and functional roles. GPR55 gene expression displayed region-specific diversity, increasing modestly in the prefrontal cortex (+19%) while plummeting by 51% in the nucleus accumbens. This dichotomous modulation suggests GPR55 may differentially influence cognitive and reward-related processes in the context of AUD, heralding a promising new avenue for research into addiction neurobiology.

Moreover, FAAH gene expression, encoding the enzyme responsible for degrading anandamide, was found to be significantly altered. FAAH levels decreased in the prefrontal cortex, potentially prolonging anandamide signaling in this area, whereas in the nucleus accumbens FAAH expression rose by 24%, likely curtailing anandamide availability. These opposing patterns may disrupt endocannabinoid homeostasis, modulating anxiety and reward pathways through region-specific enzymatic control.

The study’s strength is amplified by the rigorous selection of brain tissue samples sourced exclusively from the New South Wales Tissue Resource Centre in Australia. Importantly, all donors had confirmed histories of chronic alcohol use disorder without confounding illicit drug use, isolating alcohol’s specific impact on ECS gene expression. This precision facilitates clearer attribution of observed neurogenetic changes to alcohol alone, distinguishing them from polysubstance effects that have previously clouded interpretation.

Findings from this research illuminate molecular mechanisms contributing to the heightened relapse risk and impaired cognitive control characteristic of alcohol use disorder. By mapping molecular aberrations of the endocannabinoid system across critical mesocorticolimbic structures, this study delineates novel biomarkers and therapeutic targets that could catalyze the development of tailored, more efficacious interventions for AUD patients.

The collaborative effort was led by Professors Jorge Manzanares and María Salud García-Gutiérrez, along with Abraham Bailén Torregrosa, Francisco Navarrete, Auxiliadora Aracil, and Gabriel Rubio, incorporating expertise spanning neuropsychopharmacology, primary care addiction research, and clinical neuroscience. Funding support from the Carlos III Health Institute, Spanish Ministries of Science and Innovation and Health, and ISABIAL underscores national commitment to advancing addiction research.

As chronic alcohol exposure continues to impose a tremendous burden worldwide, these insights mark a critical advance in addiction biology. Deciphering the dysregulated endocannabinoid gene networks in brain regions pivotal for behavior control heralds a new frontier in understanding and mitigating alcohol addiction. By unlocking ECS’s complex signaling alterations, this work offers hope for innovative therapeutic strategies capable of reversing the neurobiological imprint of sustained alcohol abuse, potentially transforming lives affected by this pervasive disorder.

Subject of Research: Human tissue samples
Article Title: Endocannabinoid system gene expression in mesocorticolimbic brain regions of individuals with alcohol use disorder: A descriptive study
News Publication Date: 21-Dec-2025
Web References: http://dx.doi.org/10.1111/add.70293
Keywords: Alcoholism, Substance related disorders, Addiction, Diseases and disorders, Neuroscience, Clinical neuroscience, Molecular neuroscience, Neuropharmacology, Psychopharmacology, Molecular neuropharmacology, Human genetics, Genetic epidemiology, Genetic screening, Behavior genetics

Alcohol addiction, or alcohol use disorder (AUD), remains a formidable public health challenge worldwide, affecting millions and contributing substantially to morbidity and mortality rates. Historically, addiction research has often overlooked sex and gender differences, potentially obscuring key mechanisms that govern addiction susceptibility and resilience. The study conducted by Borruto, Coppola, Höglund, and colleagues addresses this gap with scientific rigor, examining how male and female rats differ in their propensity for addiction-like behaviors following alcohol exposure.

The investigators implemented a multifaceted experimental design, combining behavioral assays with advanced neurochemical analyses to elucidate the patterns of alcohol intake, seeking, and relapse between sexes. Their approach emphasizes the importance of modeling human-like addiction constructs in animals, focusing on compulsive drug use, motivation to consume alcohol, and resistance to negative consequences — hallmarks of human AUD. This meticulous methodology allows for higher translational relevance of their findings.

Initial observations reveal that female rats exhibit heightened vulnerability to several addiction-like behaviors. Notably, females demonstrated increased voluntary alcohol consumption compared to males during self-administration phases. Such escalated intake suggests intrinsic or hormonally mediated differences in reward sensitivity, possibly linked to estrogenic modulation of dopaminergic pathways in the mesolimbic circuitry—a neural substrate critically involved in reinforcing properties of addictive substances.

Further probing into motivation, the study utilized progressive ratio schedules to measure the effort animals would exert to obtain alcohol rewards. Female rats consistently outperformed males, indicating a stronger drive to attain alcohol. This metric underscores a sex-specific elevation in motivational processes that underpin the compulsive seeking of alcohol, which may translate into greater relapse rates observed clinically in women with AUD.

Stress and anxiety, often comorbid with addiction, were also scrutinized for their potential role in sex-based susceptibility differences. Behavioral tests assessing anxiety-related phenotypes revealed that females were more prone to exhibit stress-induced reinstatement of alcohol-seeking after periods of abstinence. This finding aligns with clinical observations that women with AUD frequently report stress and affective disturbances as critical relapse triggers, implicating the hypothalamic-pituitary-adrenal (HPA) axis and associated neuroendocrine mechanisms in mediating these effects.

At the neurochemical level, analyses focused on neurotransmitter systems implicated in addiction, including dopamine, GABA, and glutamate. The researchers observed sex-dependent alterations in receptor expression and neurotransmitter release within brain regions such as the nucleus accumbens and prefrontal cortex, areas integral to reward processing and executive control. These molecular discrepancies likely contribute to the divergent behavioral outcomes and may provide targets for sex-specific pharmacotherapies.

The study also examined tolerance and withdrawal phenomena, revealing that female rats developed physiological adaptations to chronic alcohol exposure more rapidly and exhibited more severe withdrawal symptoms upon cessation. Enhanced withdrawal severity may precipitate relapse, reinforcing the vicious cycle of addiction. These results are consistent with evidence suggesting women escalate from initial use to dependence more quickly than men, a phenomenon termed “telescoping.”

Importantly, the findings challenge the one-size-fits-all model of addiction treatment, advocating for a paradigm shift towards personalized interventions. By illuminating biological and behavioral sex differences, the research supports the development of gender-specific prevention and treatment protocols—including hormonal regulation strategies and neurobiological targets tailored to female-specific addiction circuits.

The implications of such research extend beyond the realm of addiction neuroscience. They call for integrating sex as a critical biological variable in preclinical studies and clinical trials to enhance therapeutic efficacy and reduce health disparities. Furthermore, these results may influence public policy and healthcare resource allocation by highlighting the need for sex-conscious approaches in addressing substance use disorders.

While this study marks a significant leap forward, the authors acknowledge the complexity of addiction etiology and the interplay of genetic, environmental, and psychosocial factors. Future research directions include exploring the influence of ovarian hormone fluctuations over different estrous cycle phases, epigenetic modifications, and the interaction between sex chromosomes and addiction vulnerability.

Moreover, investigating the intersectionality of sex with other demographic variables such as age, stress exposure history, and comorbid psychiatric conditions will enrich our understanding and inform comprehensive addiction models. Integrating multimodal imaging and transcriptomic profiling could further delineate the neural circuits and gene networks involved in sex-specific addiction pathways.

This research thus represents a pivotal contribution to addiction neuroscience, anchoring sex differences at the core of alcohol use disorder investigations. By leveraging rigorous animal models, the study offers a translational bridge to human clinical phenomena and casts light on mechanisms previously underappreciated or obscured. The prospect of developing precision medicine approaches that address the unique needs of women and men in addiction treatment stands as a promising horizon informed by this work.

Subsequent application of these findings may catalyze the advancement of novel pharmacological agents or behavioral interventions that more effectively mitigate addiction severity in a sex-specific manner. In particular, targeting neuroendocrine modulators or receptor subtypes implicated in the female-predominant vulnerability profiles may yield breakthroughs in treatment outcomes.

In conclusion, the study conducted by Borruto and colleagues illuminates the critical importance of sex as a biological determinant in alcohol addiction susceptibility and addiction-like behaviors. By dissecting the neurobiological and behavioral substrates that differentiate male and female addiction trajectories, this work paves the way for refined, more effective therapeutic strategies and enhances the scientific foundation necessary for reducing the global burden of alcohol use disorders.

Subject of Research: Sex-specific vulnerability patterns to alcohol addiction-like behaviors in rats.

Article Title: Sex-Specific patterns of vulnerability to alcohol addiction-like behaviors in rats.

Article References:
Borruto, A.M., Coppola, A., Höglund, L. et al. Sex-Specific patterns of vulnerability to alcohol addiction-like behaviors in rats. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03825-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-03825-w